Literature DB >> 11227486

Caspase-dependent and -independent death pathways in cancer therapy.

V M Kolenko1, R G Uzzo, R Bukowski, J H Finke.   

Abstract

The majority of current anticancer therapies induce tumor cell death through the induction of apoptosis. Alterations in the apoptotic pathways may determine tumor resistance to these therapies. Activation of the proteolytic cascade involving caspase family members is a critical component of the execution of cell death in apoptotic cells. However, recent studies suggest that cell death can proceed in the absence of caspases. In this review we describe the role of caspase-dependent and -independent pathways as targets for anticancer treatment. A better understanding of diverse modes of tumor cell death will help to avoid ineffective treatment and provide a molecular basis for the new strategies targeting caspase-independent death pathways in apoptosis-resistant forms of cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11227486     DOI: 10.1023/a:1009677307458

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  15 in total

1.  Berbamine inhibited the growth of prostate cancer cells in vivo and in vitro via triggering intrinsic pathway of apoptosis.

Authors:  Y Zhao; J J Lv; J Chen; X B Jin; M W Wang; Z H Su; L Y Wang; H Y Zhang
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-07-19       Impact factor: 5.554

2.  Non-apoptotic programmed cell death induced by a copper(II) complex in human fibrosarcoma cells.

Authors:  S Tardito; O Bussolati; F Gaccioli; R Gatti; S Guizzardi; J Uggeri; L Marchiò; M Lanfranchi; R Franchi-Gazzola
Journal:  Histochem Cell Biol       Date:  2006-05-30       Impact factor: 4.304

3.  The downregulation of c-Myc and its target gene hTERT is associated with the antiproliferative effects of baicalin on HL-60 cells.

Authors:  Xia Ren; Zhiyong Zhang; Jing Tian; Hengxiao Wang; Guanhua Song; Qiang Guo; Jing Tian; Yang Han; Qiong Liao; Guoqiang Liu; Huifang Ding; Guosheng Jiang
Journal:  Oncol Lett       Date:  2017-09-25       Impact factor: 2.967

Review 4.  Apoptosis and cell growth inhibition as antitumor effector functions of interferons.

Authors:  H Strander
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

5.  Implication of caspase-3 and granzyme B expression and activity in spleenocytes of ehrlich ascites carcinoma mice subjected to immunotherapy.

Authors:  Khaled Sh Azab; Soheir A Osman; Neama M El-Fatih
Journal:  N Am J Med Sci       Date:  2011-08

6.  2D and 3D-QSAR study on 4-anilinoquinozaline derivatives as potent apoptosis inducer and efficacious anticancer agent.

Authors:  Vivek Kumar Vyas; Manjunath Ghate; Hitesh Katariya
Journal:  Org Med Chem Lett       Date:  2011-10-04

7.  Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1.

Authors:  Julie S Barber-Rotenberg; Saravana P Selvanathan; Yali Kong; Hayriye V Erkizan; Tara M Snyder; S Peter Hong; Christina L Kobs; Natalie L South; Steven Summer; Philip J Monroe; Maksymilian Chruszcz; Veselin Dobrev; Perrer N Tosso; Lauren J Scher; Wladek Minor; Milton L Brown; Steven J Metallo; Aykut Üren; Jeffrey A Toretsky
Journal:  Oncotarget       Date:  2012-02

8.  CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways.

Authors:  Nathalie Voorzanger-Rousselot; Laurent Alberti; Jean-Yves Blay
Journal:  BMC Cancer       Date:  2006-03-18       Impact factor: 4.430

9.  LIGHT/IFN-γ triggers β cells apoptosis via NF-κB/Bcl2-dependent mitochondrial pathway.

Authors:  Quan-You Zheng; Zhao-Hui Cao; Xiao-Bo Hu; Gui-Qing Li; Shi-Fang Dong; Gui-Lian Xu; Ke-Qin Zhang
Journal:  J Cell Mol Med       Date:  2016-05-31       Impact factor: 5.310

10.  In vivo evolution of tumour cells after the generation of double-strand DNA breaks.

Authors:  H Mekid; O Tounekti; A Spatz; M Cemazar; F Z El Kebir; L M Mir
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.